Specify a stock or a cryptocurrency in the search bar to get a summary
Nanobiotix
NBTXNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France. Address: 60 rue de Wattignies, Paris, France, 75012
Analytics
WallStreet Target Price
11.19 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NBTX
Dividend Analytics NBTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NBTX
Stock Valuation NBTX
Financials NBTX
Results | 2019 | Dynamics |